1. Home
  2. EDIT vs NEN Comparison

EDIT vs NEN Comparison

Compare EDIT & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • NEN
  • Stock Information
  • Founded
  • EDIT 2013
  • NEN 1977
  • Country
  • EDIT United States
  • NEN United States
  • Employees
  • EDIT N/A
  • NEN N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • NEN Building operators
  • Sector
  • EDIT Health Care
  • NEN Real Estate
  • Exchange
  • EDIT Nasdaq
  • NEN Nasdaq
  • Market Cap
  • EDIT 263.7M
  • NEN 262.4M
  • IPO Year
  • EDIT 2016
  • NEN N/A
  • Fundamental
  • Price
  • EDIT $2.57
  • NEN $72.00
  • Analyst Decision
  • EDIT Buy
  • NEN
  • Analyst Count
  • EDIT 12
  • NEN 0
  • Target Price
  • EDIT $5.40
  • NEN N/A
  • AVG Volume (30 Days)
  • EDIT 1.7M
  • NEN 514.0
  • Earning Date
  • EDIT 08-12-2025
  • NEN 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • NEN 6.66%
  • EPS Growth
  • EDIT N/A
  • NEN 34.86
  • EPS
  • EDIT N/A
  • NEN 4.59
  • Revenue
  • EDIT $38,901,000.00
  • NEN $83,884,808.00
  • Revenue This Year
  • EDIT N/A
  • NEN N/A
  • Revenue Next Year
  • EDIT N/A
  • NEN N/A
  • P/E Ratio
  • EDIT N/A
  • NEN $15.69
  • Revenue Growth
  • EDIT N/A
  • NEN 4.96
  • 52 Week Low
  • EDIT $0.91
  • NEN $71.00
  • 52 Week High
  • EDIT $4.12
  • NEN $84.00
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 46.57
  • NEN 50.09
  • Support Level
  • EDIT $2.66
  • NEN $71.00
  • Resistance Level
  • EDIT $2.78
  • NEN $72.00
  • Average True Range (ATR)
  • EDIT 0.22
  • NEN 0.08
  • MACD
  • EDIT -0.02
  • NEN 0.12
  • Stochastic Oscillator
  • EDIT 39.39
  • NEN 100.00

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: